Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aptose Reports Results for the Fourth Quarter and Full Year 2019

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced...

APTO : 6.06 (+4.48%)
Aptose Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Aptose Biosciences, Inc. (NASDAQ:APTO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at...

APTO : 6.06 (+4.48%)
Factors to Know Ahead of Talos Energy's (TALO) Q4 Earnings

Talos Energy's (TALO) fourth-quarter earnings are expected to have taken a hit from lower realized commodity prices.

ABEO : 2.29 (+9.57%)
APTO : 6.06 (+4.48%)
TALO : 6.00 (+0.17%)
ALEC : 23.43 (+6.99%)
Daqo New Energy (DQ) to Post Q4 Earnings: What's in Store?

Our proven model does not conclusively predict an earnings beat for Daqo New Energy (DQ) this season.

BLFS : 10.29 (+4.57%)
DQ : 52.68 (+2.45%)
APTO : 6.06 (+4.48%)
AZUL : 8.87 (+11.99%)
Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results...

APTO : 6.06 (+4.48%)
Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

APTO : 6.06 (+4.48%)
Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the company...

APTO : 6.06 (+4.48%)
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

APTO : 6.06 (+4.48%)
Aptose Biosciences to Present at Biotech Showcase(TM) 2020 Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G....

APTO : 6.06 (+4.48%)
Aptose Announces Closing of Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the "Offering")...

APTO : 6.06 (+4.48%)
Aptose Announces Pricing of Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the "Offering")...

APTO : 6.06 (+4.48%)
Aptose Announces Proposed Public Offering of Common Shares

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the "Offering"). In addition, Aptose...

APTO : 6.06 (+4.48%)
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019

Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat...

CNSP : 2.20 (+1.85%)
CLVS : 6.80 (+11.48%)
ARQL : 20.00 (+0.15%)
APTO : 6.06 (+4.48%)
APS.TO : 8.51 (+3.91%)
FATE : 24.80 (+8.11%)
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting

Aptose Biosciences Inc. ("Aptose") (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the presentation...

APTO : 6.06 (+4.48%)
Aptose Presents Highlights From Corporate Event At ASH

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today held at the 61 American Society of Hematology (ASH) Annual Meeting and Exposition in...

APTO : 6.06 (+4.48%)
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of...

APTO : 6.06 (+4.48%)
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose...

APTO : 6.06 (+4.48%)
Aptose to Present at BIO-Europe Conference

Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose...

APTO : 6.06 (+4.48%)
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting

- Company to Hold Event During ASH -

APTO : 6.06 (+4.48%)
Aptose Reports Results for the Third Quarter Ended September 30, 2019

CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate

APTO : 6.06 (+4.48%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +6.62 , SEDG +10.67 , THC +1.63 , TER +6.34 , LITE +7.94
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar